Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 3 10Phase 1 4Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Breast 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 17Radiotherapy 8pembrolizumab 7Radiotherapy, Intensity-Modulated 7Fluorouracil 7Magnetic Resonance Spectroscopy 6Docetaxel 6Platinum 5Gemcitabine 51,2-diaminocyclohexaneplatinum II citrate 5Paclitaxel 4Specimen Handling 3Radiation 3Drug Therapy 3Cetuximab 3Carboplatin 3(225)Ac-DOTA-c(RGDyK) 3atezolizumab 2Iodine-123 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Disulfides 2Biopsy 2trametinib 1toripalimab 1ponatinib 1pertuzumab 1nimotuzumab 1fosbretabulin 1fluorocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × camrelizumab × Head & Neck × Clear all
NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
460 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡